Board Chairman and CEO
QIAGEN (Suzhou) Translational Medicine Co., Ltd
With 25 years of drug R&D experience and years of experience in translational science and diagnostics, Nick is now the board chairman and CEO for QIAGEN (Suzhou) Translational Medicine Co., Ltd, which is an integrated precision medicine diagnostic solution provider for biomarker, companion diagnostics development and clinical testing. Nick was China GM and Corporate SVP for Frontage Lab, and a founding director and executive for Novartis China R&D center. Before that, Nick was a director at US OSI Pharmaceuticals and a manager at Pfizer global R&D center. Nick filed 6 INDs/IMPD and 1 NDA/MAA for various dosage forms.
Nick represented Pfizer serving on the PRQI working committee (formed among FDA, industry and academia) and also represented Bayhelix serving on sFDA CMC working committee. Before going to US, Nick worked and studied at Chinese Academy of Sciences. And he got his Ph.D. degree from University of Cincinnati.
Nick is now a member of Bayhelix, a global association of Chinese Life Science Business Executives; an invited vice president of Jiangsu Life Science and Technology Association; and a director of Biomedical Committee (SEBMC), Sino-EU Chemical/Manufacturer Association. He is one of 5 founders and deputy director for China Precision Medicine and Companion Diagnostics Consortium. Nick is the recipient of the China Suzhou SIP Leading Talent Award, China Jiangsu Province Entrepreneur and Innovation Talent Award, and China national One-Thousand-Plan Talent Expert Award.